IONIS PHARMACEUTICALS INC Insider Trading Activity
Every SEC Form 4 insider transaction reported for IONIS PHARMACEUTICALS INC (IONS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are IONS insiders buying or selling?
In the last 12 months, IONIS PHARMACEUTICALS INC insiders reported 1 open-market purchase ($1.1M) and 68 sales ($134.0M) — net selling of $133.0M. Since January 2018, Trabud has recorded 335 Form 4 filings for IONS: 3 buys ($1.7M) and 332 sells ($316.3M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $1.1M by Michael R Hayden (Director) on Jul 31, 2026. SEC ↗
- The most recent open-market purchase was reported on Jul 31, 2026 (2 months ago).
Key Statistics (January 2018 – Jul 31, 2026)
Total Form 4 filings
335
SEC EDGAR
Insider filers
25
Insider buys (3)
$1.7M
Insider sells (332)
$316.3M
Insider sentiment
Net sellingNet insider flow of $314.6M in net selling since January 2018, and $133.0M in net selling over the last 12 months. 1 insider buy in the last 90 days.
Recent IONS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | Michael R Hayden | Director | Purchase | 20.0K | $52.94 | $1.1M | SEC ↗ |
| Jul 9, 2026 | BENNETT C FRANK | EVP, Chief Scientific Officer | Sale | 20.5K | $84.95 | $1.7M | SEC ↗ |
| Jul 9, 2026 | Allene M. Diaz | Director | Sale | 10.1K | $85.42 | $863.6K | SEC ↗ |
| Jul 9, 2026 | Holly B. Kordasiewicz | EVP, Chief Development Officer | Sale | 362 | $84.30 | $30.5K | SEC ↗ |
| Jul 6, 2026 | Joseph Klein III | Director | Sale | 11.5K | $79.04 | $910.4K | SEC ↗ |
| Jun 30, 2026 | Joseph Baroldi | EVP, Chief Business Officer | Sale | 5.6K | $80.16 | $451.7K | SEC ↗ |
| Jun 30, 2026 | Patrick R. O'Neil | EVP CLO & General Counsel | Sale | 3.1K | $80.00 | $245.5K | SEC ↗ |
| Jun 30, 2026 | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | Sale | 26.0K | $81.05 | $2.1M | SEC ↗ |
| Jun 26, 2026 | Brett P Monia | Chief Executive Officer | Sale | 85.6K | $79.70 | $6.8M | SEC ↗ |
| Jun 26, 2026 | Eric Swayze | EVP Research | Sale | 10.6K | $79.18 | $839.5K | SEC ↗ |
| Jun 16, 2026 | Holly B. Kordasiewicz | EVP, Chief Development Officer | Sale | 60.8K | $73.41 | $4.5M | SEC ↗ |
| Jun 16, 2026 | BERTHELSEN SPENCER R | Director | Sale | 8.0K | $73.49 | $587.9K | SEC ↗ |
| Jun 3, 2026 | BERTHELSEN SPENCER R | Director | Sale | 8.0K | $75.67 | $605.4K | SEC ↗ |
| May 15, 2026 | Brett P Monia | Chief Executive Officer | Sale | 4.5K | $78.49 | $356.0K | SEC ↗ |
| May 6, 2026 | Joseph Loscalzo | Director | Sale | 77.3K | $75.06 | $5.8M | SEC ↗ |
| May 5, 2026 | Joseph Klein III | Director | Sale | 10.1K | $73.51 | $743.2K | SEC ↗ |
| Apr 30, 2026 | Joseph Baroldi | EVP, Chief Business Officer | Sale | 1.6K | $71.79 | $116.7K | SEC ↗ |
| Apr 17, 2026 | Lynne B Parshall | Director | Sale | 5.0K | $76.27 | $381.4K | SEC ↗ |
| Apr 17, 2026 | Kyle Jenne | EVP, Chf GL Pdt Str Ofcr | Sale | 4.9K | $75.17 | $368.5K | SEC ↗ |
| Apr 17, 2026 | Brian Birchler | EVP, Corp and Development Ops | Sale | 973 | $75.04 | $73.0K | SEC ↗ |
| Apr 17, 2026 | Joseph Baroldi | EVP, Chief Business Officer | Sale | 5.6K | $74.56 | $419.0K | SEC ↗ |
| Apr 2, 2026 | Joseph Klein III | Director | Sale | 22.3K | $75.55 | $1.7M | SEC ↗ |
| Apr 2, 2026 | Shannon L. Devers | EVP, Chief Human Resources Ofc | Sale | 6.2K | $74.05 | $458.6K | SEC ↗ |
| Mar 23, 2026 | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | Sale | 5.8K | $70.97 | $412.5K | SEC ↗ |
| Mar 18, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | Sale | 225.2K | $72.43 | $16.3M | SEC ↗ |
Showing the 25 most recent of 335 Form 4 filings for IONIS PHARMACEUTICALS INC.
Most active IONS insiders
- Brett P Monia42 filings
- Patrick R. O'Neil36 filings
- BENNETT C FRANK28 filings
- Joseph Klein III28 filings
- Eric Swayze24 filings
Ask anything about IONS insider activity
Use Trabud's AI agent to query IONIS PHARMACEUTICALS INC's Form 4 history in plain English — "Show me IONS CEO purchases this year" or compare it against any other ticker.
Open the AI agentIONS insider trading FAQ
Are IONIS PHARMACEUTICALS INC insiders buying or selling?
In the last 12 months, IONIS PHARMACEUTICALS INC insiders reported 1 open-market purchase ($1.1M) and 68 sales ($134.0M) — net selling of $133.0M. Since January 2018, Trabud has recorded 335 Form 4 filings for IONS: 3 buys ($1.7M) and 332 sells ($316.3M). Over the full record that is net selling of $314.6M.
How many insiders trade IONS stock?
25 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for IONIS PHARMACEUTICALS INC. The most recent filing was accepted on Jul 31, 2026.
Where does Trabud get IONS insider trading data?
All IONS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.